Merck and Pfizer Earnings: What to Expect
Merck and Pfizer are set to report their most recent quarterly results before the opening bell tomorrow. Pfizer is one of the most shorted of all Dow stocks.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 82
It’s Not the FDA Holding Back This New Pneumonia Treatment
Melinta shares dropped on Friday even though the firm announced that the FDA has approved Baxdela (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia.
Major Biotechs See Rising Tide in Short Interest
The October 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Short Sellers Can’t Make Up Their Minds on Big Pharma
The October 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Eli Lilly Just Couldn’t Get It Together in Q3
Eli Lilly shares retreated after it released mixed third-quarter financial results before the markets opened on Wednesday.
Eton Pharma Wins Big With FDA Hypotension Treatment Approval
Eton Pharma shares jumped on Tuesday after the firm announced that the FDA has approved Biorphen for treatment of hypotension.
Why Biogen’s Alzheimer’s Study Is Overshadowing Its Big Earnings Beat
Biogen released its third-quarter financial results and Alzheimer’s trial news before the markets opened on Tuesday.
Big Step Forward in HER2-Positive Breast Cancer Trial
Seattle Genetics shares jumped on Monday after the firm announced positive results from its midstage breast cancer trial.
How Biotech and Big Pharma Have Upside Heading Into Earnings
Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.
Opioid Crisis Has Cost US Economy $631 Billion
Over the past four years, the economic cost of the opioid epidemic has cost the United States some $631 billion. And with more deaths possible, the costs could soar.
A Crucial Major Depressive Disorder Study Is About to Be Underway
Axsome Therapeutics shares made a handy gain on Wednesday after the firm announced that it has completed patient enrollment in its Gemini study, a Phase 3 trial of AXS-05 in patients with major depressive…
Are Shareholders Getting Enough in the Achillion Acquisition?
Achillion Pharmaceuticals shares skyrocketed on Wednesday morning on news that the firm would be acquired by Alexion Pharmaceuticals.
Why This Neuromuscular Disorder Study Could Be the Next Big Thing
Reata Pharma shares jumped on Tuesday after the firm announced positive results from its midstage neuromuscular disorder drug trial.
Johnson & Johnson Offers a Strong Start to Earnings Season
Johnson & Johnson reported better than expected quarterly results before the markets opened on Tuesday.
UnitedHealth Helps Save the Dow With Q3 Earnings
UnitedHealth reported better than expected third-quarter financial results before the markets opened on Tuesday.